Forward progress FDA IS REPORTEDLY EXPECTED TO LIFT RESTRICTION ON PEPTIDES NYT FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog Peptides in 2026, What the FDA Review Means Olympia Pharmaceuticals of the Federal Food, Drug, and Cosmetic Act (FDCA).* FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of